• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于基层医疗的路易体痴呆血液筛查试验

A Blood Screening Test for Dementia with Lewy Bodies for Primary Care.

作者信息

Petersen Melissa, Ferman Tanis J, Zhang Fan, Pedraza Otto, Wszolek Zbigniew K, Ross Owen A, Como Tori, Julovich David, Johnson Leigh A, Hall James, Graff-Radford Neill R, O'Bryant Sid E

机构信息

Department of Psychology, Institute for Translational Research, University of North Texas Health Science Center, Fort Worth, Texas, USA.

Department of Family Medicine, University of North Texas Health Science Center, Fort Worth, Texas, USA.

出版信息

J Alzheimers Dis Parkinsonism. 2023;13(6). Epub 2023 Dec 4.

PMID:40688520
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12276881/
Abstract

INTRODUCTION

We sought to cross-validate our previously published blood test for detecting Dementia with Lewy Bodies (DLB).

METHOD

Plasma samples were analyzed on 428 individuals (DLB n=89, Parkinson's Disease (PD) without dementia n=126, Alzheimer's Disease (AD) n=108, Normal Controls (NC) n=105).

RESULTS

The proteomic profile discriminated DLB and PD from NC with an AUC (Area Under the Curve) of 0.96 with demographics of age, sex and education. The proteomic profile also distinguished DLB from the PD group with an AUC of 0.92 with demographics. It further distinguished DLB, PD and AD from NC with an AUC of 0.95 as well as DLB from AD with an AUC of 0.92 with demographics.

DISCUSSION

This data provides additional evidence of the potential utility of a multi-tiered blood-based proteomic screening method for detecting DLB and distinguishing DLB from NC, PD and AD that can be implemented in primary care settings to aid in the referral process.

摘要

引言

我们试图对我们之前发表的用于检测路易体痴呆(DLB)的血液检测方法进行交叉验证。

方法

对428名个体的血浆样本进行分析(DLB组89例,无痴呆的帕金森病(PD)组126例,阿尔茨海默病(AD)组108例,正常对照组(NC)105例)。

结果

蛋白质组学图谱在纳入年龄、性别和教育程度等人口统计学因素后,区分DLB和PD与NC的曲线下面积(AUC)为0.96。蛋白质组学图谱在纳入人口统计学因素后,区分DLB与PD组的AUC为0.92。在纳入人口统计学因素后,它区分DLB、PD和AD与NC的AUC为0.95,区分DLB与AD的AUC为0.92。

讨论

该数据为基于血液的多层蛋白质组学筛查方法在检测DLB以及区分DLB与NC、PD和AD方面的潜在效用提供了更多证据,该方法可在初级保健机构中实施,以辅助转诊过程。

相似文献

1
A Blood Screening Test for Dementia with Lewy Bodies for Primary Care.用于基层医疗的路易体痴呆血液筛查试验
J Alzheimers Dis Parkinsonism. 2023;13(6). Epub 2023 Dec 4.
2
Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.用于路易体痴呆、帕金森病痴呆及帕金森病认知障碍的胆碱酯酶抑制剂
Cochrane Database Syst Rev. 2012 Mar 14;2012(3):CD006504. doi: 10.1002/14651858.CD006504.pub2.
3
Dopamine transporter imaging for the diagnosis of dementia with Lewy bodies.用于诊断路易体痴呆的多巴胺转运体成像
Cochrane Database Syst Rev. 2015 Jan 30;1(1):CD010633. doi: 10.1002/14651858.CD010633.pub2.
4
Tissue Factor and Its Cerebrospinal Fluid Protein Profiles in Parkinson's Disease.组织因子及其在帕金森病中的脑脊液蛋白谱。
J Parkinsons Dis. 2024;14(7):1405-1416. doi: 10.3233/JPD-240115.
5
Prevalence, distribution, and severity of cerebral amyloid angiopathy differ between Lewy body diseases and Alzheimer's disease.路易体病和阿尔茨海默病的脑淀粉样血管病的患病率、分布和严重程度不同。
Acta Neuropathol Commun. 2024 Feb 15;12(1):28. doi: 10.1186/s40478-023-01714-7.
6
Distinguishing Prodromal Dementia With Lewy Bodies From Prodromal Alzheimer Disease: A Longitudinal Study.区分前驱期路易体痴呆与前驱期阿尔茨海默病:一项纵向研究。
Neurol Clin Pract. 2025 Feb;15(1):e200380. doi: 10.1212/CPJ.0000000000200380. Epub 2024 Oct 8.
7
Systematic review and meta-analysis show that dementia with Lewy bodies is a visual-perceptual and attentional-executive dementia.系统评价和荟萃分析表明,路易体痴呆是一种视知觉和注意-执行功能型痴呆。
Dement Geriatr Cogn Disord. 2003;16(4):229-37. doi: 10.1159/000072807.
8
High-sensitivity plasma proteomics reveals disease-specific signatures and predictive biomarkers of Alzheimer's disease phenotypes in a large mixed dementia cohort.高灵敏度血浆蛋白质组学揭示了大型混合性痴呆队列中阿尔茨海默病表型的疾病特异性特征和预测性生物标志物。
Res Sq. 2025 Jun 29:rs.3.rs-6440485. doi: 10.21203/rs.3.rs-6440485/v1.
9
Streamlined alpha-synuclein RT-QuIC assay for various biospecimens in Parkinson's disease and dementia with Lewy bodies.用于帕金森病和路易体痴呆症各种生物样本的简化α-突触核蛋白实时无细胞扩增检测法
Acta Neuropathol Commun. 2021 Apr 7;9(1):62. doi: 10.1186/s40478-021-01175-w.
10
Cholinesterase inhibitors for dementia with Lewy bodies.用于路易体痴呆的胆碱酯酶抑制剂。
Cochrane Database Syst Rev. 2003;2003(3):CD003672. doi: 10.1002/14651858.CD003672.

本文引用的文献

1
Subtypes of dementia with Lewy bodies are associated with α-synuclein and tau distribution.路易体痴呆的亚型与α-突触核蛋白和 tau 分布有关。
Neurology. 2020 Jul 14;95(2):e155-e165. doi: 10.1212/WNL.0000000000009763. Epub 2020 Jun 19.
2
Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia.阿尔茨海默病患者血浆 P-tau181:与其他生物标志物的关系、鉴别诊断、神经病理学和向阿尔茨海默病痴呆的纵向进展。
Nat Med. 2020 Mar;26(3):379-386. doi: 10.1038/s41591-020-0755-1. Epub 2020 Mar 2.
3
Potential two-step proteomic signature for Parkinson's disease: Pilot analysis in the Harvard Biomarkers Study.
帕金森病潜在的两步蛋白质组学特征:哈佛生物标志物研究中的初步分析。
Alzheimers Dement (Amst). 2019 May 2;11:374-382. doi: 10.1016/j.dadm.2019.03.001. eCollection 2019 Dec.
4
A proteomic signature for dementia with Lewy bodies.路易体痴呆的蛋白质组学特征。
Alzheimers Dement (Amst). 2019 Mar 15;11:270-276. doi: 10.1016/j.dadm.2019.01.006. eCollection 2019 Dec.
5
Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic.阿尔茨海默病的基于血液的生物标志物:为走向临床铺平道路。
Nat Rev Neurol. 2018 Nov;14(11):639-652. doi: 10.1038/s41582-018-0079-7.
6
Rapid and ultra-sensitive quantitation of disease-associated α-synuclein seeds in brain and cerebrospinal fluid by αSyn RT-QuIC.采用 αSyn RT-QuIC 技术快速且超灵敏定量脑和脑脊液中与疾病相关的 α-突触核蛋白种子。
Acta Neuropathol Commun. 2018 Feb 9;6(1):7. doi: 10.1186/s40478-018-0508-2.
7
Biomarkers for Parkinson's Disease: Recent Advancement.帕金森病的生物标志物:最新进展。
Neurosci Bull. 2017 Oct;33(5):585-597. doi: 10.1007/s12264-017-0183-5. Epub 2017 Sep 21.
8
Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium.路易体痴呆的诊断与管理:DLB联盟第四次共识报告
Neurology. 2017 Jul 4;89(1):88-100. doi: 10.1212/WNL.0000000000004058. Epub 2017 Jun 7.
9
Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic.阿尔茨海默病的血液生物标志物:科学现状及从发现到临床推进的新型合作模式。
Alzheimers Dement. 2017 Jan;13(1):45-58. doi: 10.1016/j.jalz.2016.09.014. Epub 2016 Nov 18.
10
A blood screening test for Alzheimer's disease.一种用于阿尔茨海默病的血液筛查测试。
Alzheimers Dement (Amst). 2016 Jun 25;3:83-90. doi: 10.1016/j.dadm.2016.06.004. eCollection 2016.